SMC
DGX icon

Smith, Moore & Co’s Quest Diagnostics DGX Stock Holding History

Smith, Moore & Co’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,390
Closed -$274K – 352
2020
Q3 		$274K Buy
2,390
+6
+0.3% +$709 0.06% 264
2020
Q2 		$272K Buy
+2,384
New +$253K 0.06% 252

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Smith, Moore & Co's DGX Position: Q4 2020 in Review

Smith, Moore & Co sold out of Quest Diagnostics (DGX) in Q4 2020, closing a stake of 2,390 shares — an estimated $274K sold.

Smith, Moore & Co first reported a position in DGX in Q2 2020 and held it in 2 quarters. The position peaked at $274K in Q3 2020. 811 funds tracked by Wall St. Rank hold DGX as of Q4 2020.

  • Smith, Moore & Co reported no remaining Quest Diagnostics position as of Q4 2020 after selling out during the quarter.
  • Smith, Moore & Co sold 2,390 Quest Diagnostics shares in Q4 2020, an estimated $274K.
  • Smith, Moore & Co first reported a position in Quest Diagnostics in Q2 2020 and held it in 2 quarters.
  • Smith, Moore & Co's Quest Diagnostics position peaked at $274K in Q3 2020.
  • 811 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2020.

Based on Smith, Moore & Co's 13F filing for Q4 2020, filed 16 Feb 2021.